Biblio Discovery — Demo Discovery Service

4 results for "Rob Hagendijk"

Showing 1–4 · 1.14 seconds · RSS

  1. Journal Article

    Constructing a single market for pharmaceuticals in the EU: what’s the price?

    Tineke Kleinhout-Vliek; Susi Geiger; Rob Hagendijk et al.

    Health Economics, Policy and Law, Vol. 21 · 2026 · English · DOAJ Scopus

    The European Union (EU) is currently overhauling its pharmaceutical regulations, seeking to mature a single market for medicines as part of a ‘European Health Union’. We reflect on the interactions between regulations and markets in these reforms and investigate what this single market for…

  2. Journal Article

    How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases

    Conor M. W. Douglas; Tineke Kleinhout-Vliek; Rob Hagendijk et al.

    Orphanet Journal of Rare Diseases, Vol. 20 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background The current organization of the pharmaceutical innovation system poses three major challenges for rare disease patients in terms of availability, accessibility and affordability of treatments. While some changes have emerged in the European Union to address some of these…

  3. Journal Article

    Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases

    Conor M. W. Douglas; Fernando Aith; Wouter Boon et al.

    Orphanet Journal of Rare Diseases, Vol. 17 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Rare diseases are associated with difficulties in addressing unmet medical needs, lack of access to treatment, high prices, evidentiary mismatch, equity, etc. While challenges facing the development of drugs for rare diseases are experienced differently globally (i.e., higher vs. lower and…